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This paper reports preliminary results with intensity-modulated radiotherapy (IMRT) in nasopharyngeal
carcinoma (NPC). Between August 2000 and May 2001, we treated 19 patients with NPC using IMRT.
Twelve patients had stage I–II disease and seven had stage III–IV disease. Six patients received 9.0–
19.8 Gy three-dimensional conformal radiotherapy (3D-CRT) before IMRT and 18 patients received a
brachytherapy boost after IMRT. The mean follow-up time was 13.0 months. All patients with stage II–
IV disease except one received two cycles of chemoradiotherapy with cisplatin and 5-fluorouracil
(5-FU) during radiotherapy, followed by two to four cycles of chemotherapy after radiotherapy. Tumor
response was assessed using clinical examination and computerized tomography or magnetic resonance
imaging. The mean doses administered to the gross tumor volume and clinical tumor volume were
70.9 Gy and 63.2 Gy, respectively. The mean doses administered to the right and left parotid glands were
38.1 Gy and 38.6 Gy, respectively. All 19 patients had a complete response of primary and lymph node
disease. Grade III mucositis developed during chemoradiotherapy in 15 patients (79%). In addition, clinical
grade I xerostomia was recorded in nine patients, grade II in nine, and grade III in one. This study
demonstrated that 3D-CRT, IMRT, intracavitary brachytherapy, and chemotherapy are effective and safe
methods to treat NPC. Although IMRT treatment spared parotid gland function, its efficacy may be
significantly influenced by disease stage and location of the neck lymph nodes. More cases and a longer
follow-up to assess survival and complications are planned.
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Radiotherapy is the main treatment for nasopharyngeal
carcinoma (NPC). Long-term survival rates can reach 40%
to 90%, depending on the tumor stage [1,2]. While a high
percentage of patients can be cured by radiotherapy, their
quality of life is greatly impaired by treatment sequelae [3,
4]. Xerostomia is a chronic complication of treatment that
affects eating, swallowing, and speaking. Additionally, the
sores may become infected. However, because the salivary
glands lie within the treatment field in bilaterally opposed
portals, the development of xerostomia is inevitable.
Three-dimensional conformal radiotherapy (3D-CRT)
and intensity-modulated radiotherapy (IMRT) can deliver
the radiation dose to the target volume while only exposing
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nearby critical organs to low doses [3,5,6]. IMRT produces
more complex three-dimensional dose distributions than
3D-CRT [6,7]. These results suggest that parotid-sparing
radiotherapy for NPC may be achievable with IMRT [8,9].
Previous investigators have reported the use of IMRT
for NPC, but few reports included simultaneous chemo-
therapy [8–10]. The safety of the combination of IMRT and
chemotherapy, especially with 5-fluorouracil (5-FU),
requires further study. This paper reports preliminary results
in the first 19 patients treated primarily with IMRT and
chemotherapy, with emphasis on the side effects of
treatment.
MATERIALS AND METHODS
From August 2000 to May 2001, 22 patients with
histologically proven NPC were treated using IMRT in the
Department of Radiation Oncology at Chung Shan Medical
University Hospital. Three cases were excluded from the
analysis because the gross tumor volume (GTV) received
less than 56 Gy or the conventional bilaterally opposed
fields received more than 20 Gy. The remaining 19 patients,
14 males and five females, were included in the analysis.
Their ages ranged from 21 to 73 years (median, 47.6 years).
Pretreatment evaluation included a complete history
and physical examination, complete blood count, liver and
renal function tests, fiber optic endoscopy, chest roent-
genography, magnetic resonance imaging (MRI) or com-
puterized tomography (CT) of the nasopharynx and neck,
bone scan, liver sonography, and dental evaluation. The
disease was staged according to the 1997 American Joint
Committee on Cancer (AJCC) staging classification [11].
The disease was classified as stage I in seven patients, stage
II in five, stage III in five, and stage IV in two (Table 1).
Histopathologic analysis confirmed non-keratinizing
carcinoma (World Health Organization, WHO, II) in four
patients and undifferentiated carcinoma (WHO III) in 15
patients.
Before image acquisition, all patients were immobilized
in a supine position with head support and a thermoplastic
mask. A volumetric CT image was acquired using a CT
simulator (GE HiSpeed CT/1, GE Medical Systems,
Milwaukee, WI, USA) coupled with a LAP4 laser (PatPos
CTI/DUO; LAP Laser Applikationen GmbH, Lüneburg,
Germany), and the image data were transferred to a
SomaVision System (Varian Corporation, Palo Alto, CA,
USA) for tumor contour and critical organ segmentation.
The CT scan slice thickness was 3 mm throughout the
scanned region. After all the targets and critical organs were
identified, the data were transferred to an inverse planning
system (Helio Planning System, Varian Corporation) for
IMRT planning. Before treatment, treatment position was
verified using portal images acquired using the PortalVision
System (Varian Corporation). The GTV of a nasopharyngeal
tumor was defined as the volume of gross visible tumor
plus margins of 2 mm to 4 mm. The GTV for positive lymph
node(s) was defined as the volume of gross visible metastatic
lymph node(s) plus margins of 2 mm to 4 mm. The clinical
tumor volume (CTV) was defined as the GTV plus a margin
including the skull base, inferior two-thirds of the sphenoid
sinus, the entire nasopharynx, retropharyngeal nodes,
pterygoid fossae, posterior nasal cavity, posterior half
maxillary sinuses, and parapharyngeal space. The planning
target volume (PTV) was defined as the CTV plus 3 mm
margins. To minimize the field-to-field junction error, the
upper and lower neck regions were irradiated using an
anterior–posterior (AP) portal with the same isocenter as
IMRT treatment.
To design an inverse plan with the potential to provide
both physical and biologic benefit, we assigned different
doses to different targets, similar to the concept of
simultaneous integrated boost. The goal was to deliver a
minimum dose of 70 Gy to the GTV, 55–60 Gy to the CTV,
and 65–70 Gy to the metastatic lymph node(s) with fraction
sizes of 2.12 Gy, 1.7–1.8 Gy, and 2.0–2.12 Gy, respectively.
The dose regimen was designed to keep the CTV target
receiving conventional fractionation but to accelerate the
dose to the GTV target. Therefore, this schedule could be
considered a semi-accelerated radiotherapy schedule. The
dose constraints to critical organs were 50 Gy to the brain
stem, 40 Gy to the spinal cord, 45 Gy to the optic chiasm, and
33–35 Gy to the parotid glands. Six patients had received
3D-CRT of 9.0–18.0 Gy before IMRT began. The 3D-CRT
treatment consisted of one AP and two bilaterally opposed
portals with a daily fraction of 1.8 Gy. IMRT was delivered
via seven fixed-gantry angles with a Varian 21EX Linear
Accelerator (Varian Corporation). Before treatment, all plans
underwent a quality assurance test that included a film
isodose curve comparison and absolute dose check with an
ion-chamber at the isocenter under a cylindrical water
phantom designed in-house.
IMRT plans were prepared using the Helio inverse
planning system. Pre-selected coplanar beams were used at
non-equiangular spacing for all NPC plans in this study.
The spinal cord and brain stem, treated as serial organs,
were defined by a dose-based objective function with dose
limits of less than 40 Gy and 50 Gy, respectively. As the
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parotid glands were proximal to the CTV, a high dose could
not be prevented from reaching the parotid–CTV overlap
region. We utilized a dose volume constraint for the parotid
glands to allow less than 50% of the parotid volume to
receive a dose higher than 35 Gy. After clinical parameters
were set for the objective function, an engine based on a
conjugate gradient algorithm searched for the optimal
fluences to minimize the score function, or the general form
of the objective function combined from the separate target
and organ-at-risk objective functions with different priority
factor settings.
Eighteen cases received a brachytherapy boost of 7.0 Gy
given in two fractions after IMRT treatment. The dose
calculation point was defined at the skull base. Distances
from this point to the sources ranged from 1.2 cm to 2.5 cm
as measured by lateral simulation film. All stage II–IV
cases except one received concurrent chemoradiotherapy
with cisplatin (60 mg/m2 on days 1 and 28) and 5-FU
(600 mg/m2 on days 1–4 and 28–31), with two cycles given
during radiotherapy and two to four cycles following
radiotherapy.
Salivary function was evaluated by both subjective and
objective methods. The subjective method for grading
xerostomia was based on clinical symptoms: grade 0, no
symptoms; grade 1, mild mouth dryness, able to eat meals
without liquid; grade 2, moderate mouth dryness, always
needs liquid while eating; grade 3, severe or complete dry-
ness, usually wakes up at night to drink liquids [3]. Func-
tional radioisotope (RI) sialography, sialoscintigraphy, was
the objective method to evaluate parotid gland function.
Tests were carried out before the start of radiotherapy and
repeated 1, 3, and 6 months after the completion of radio-
therapy. The secretion ratio (SR) at 6 months was used as
the post-irradiated value for statistical comparison. Func-
tional RI sialography has been described in detail by Tsujii
[12]. SR is calculated by dividing the decrease in RI count
after acid stimulation by the RI count before stimulation.
Parotid gland SR is used as an objective method for
estimation of salivary function pre- and postradiotherapy.
After completing radiotherapy, patients were evaluated
every month for the first 3 months, then every 2–3 months
for the next 6–15 months. A physical examination including
a mirror examination or fiber optic endoscopy and palpation
of the neck was performed at each visit. Post-treatment MRI
or CT scan from the skull base to the neck was obtained
2–3 months after the completion of radiotherapy. MRI or CT
examination was repeated every 6 months, while fiber
optic endoscopy was performed every 3–6 months. The
Table 1. Characteristics of patients undergoing precision-oriented radiation therapy techniques including intensity-modulated
radiotherapy (IMRT)
Gender Age T N CRT (Gy) IMRT (Gy) Brachy C/T Xero
F 53 1 0 0 71.3 No No 2
M 52 2 1 0 72.5 Yes Yes 2
F 70 2 1 0 71.9 Yes Yes 2
M 42 1 2 0 70.7 Yes Yes 1
M 49 1 0 0 71.6 Yes No 1
M 53 2 2 9.0 64.7 Yes Yes 1
M 25 1 1 0 69.5 Yes Yes 1
M 73 2 0 9.0 60.9 Yes No 2
M 60 1 0 9.0 63.3 Yes No 2
F 35 3 2 0 71.9 Yes Yes 1
M 56 1 0 0 70.4 Yes No 1
M 38 2 2 9.0 60.6 Yes Yes 2
F 73 2 1 0 71.4 Yes Yes 2
M 29 1 0 0 69.8 Yes No 1
F 36 1 0 0 70.6 Yes No 1
M 21 2 2 0 69.8 Yes Yes 2
M 41 4 1 9.0 65.9 Yes Yes 2
M 51 1 0 0 71.4 Yes No 1
M 47 4 2 19.8 54.7 Yes Yes 3
T = tumor status according to 1997 AJCC TNM staging system; N = nodal status according to 1997 AJCC TNM staging system; CRT = 3-dimensional
conformal radiotherapy; Brachy = intracavitary brachytherapy boost; C/T = chemotherapy; Xero = xerostomia clinical grading [3].
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follow-up time was defined from the end of radiotherapy to
March 2002 and ranged from 8 to 18 months (mean, 13.0
months).
The Wilcoxon signed-rank test was used to compare
differences in the SR of parotid glands pre- and post-
radiotherapy. The α error was defined as 0.05. SPSS version
10 (SPSS Inc, Chicago, IL, USA) was used for all statistical
analyses.
RESULTS
Table 2 lists the doses prescribed and delivered to the
targets and critical organs. The GTV was prescribed a total
dose of 70.0 Gy to 73.6 Gy (mean, 70.8 Gy). Five patients
received 3D-CRT with 9.0 Gy in five fractions and one
received 19.8 Gy in 11 fractions prior to IMRT. The fraction
size in IMRT was 2.12 Gy in 18 patients and 2.0 Gy in one
patient. The CTV was prescribed a total dose of 56 Gy in 17
patients and 50 Gy and 60 Gy, respectively, in the remaining
two patients. The mean doses to the GTV and the CTV were
70.9 Gy and 63.2 Gy, respectively. The mean 95% volume
dose to the GTV and the CTV were 70.0 Gy and 55.0 Gy,
respectively. For the total dose, we calculated the sum of the
doses from 3D-CRT and IMRT plans. The spinal cord, brain
stem, and optic chiasm received mean doses of 36.4 Gy,
34.9 Gy, and 39.9 Gy, respectively, which was lower than
the preset dose constraint. However, the mean dose to the
bilateral parotid glands (37.5 and 38.1 Gy) was slightly
higher than the mean preset constraint of 50% volume dose
(34.6 and 34.5 Gy). The dose per fraction to the parotid
glands ranged from 0.47 to 1.8 Gy.
Seventeen patients completed the entire course of
radiotherapy within 54 days; the remaining two patients
completed it within 60 days due to treatment interruption
for grade III mucositis. All stage II–IV patients received
concurrent chemoradiotherapy and 18 patients (94.7%)
received treatment using a semi-accelerated dose schedule.
All stage II–IV patients (12 cases) and three of seven stage I
patients developed grade III mucositis (79%). Tube feeding
during concurrent chemoradiotherapy was necessary for
five patients (26.3%). Weight loss of at least 10% of
pretreatment body weight occurred in 11 patients (57.8%).
Only one patient had a grade III skin reaction at the field-to-
field junction line. Grade I and II skin reactions occurred in
11 and 7 patients, respectively. Nine patients each developed
grade I and II xerostomia 6 months after radiotherapy. One
patient who had grade III xerostomia had received a 3D-
CRT dose of 19.8 Gy prior to IMRT treatment. All 19 patients
had an initial complete response evaluated at 2–3 months
after completion of IMRT treatment. No locoregional
recurrence was found during a mean follow-up of 13 months
(range, 8–18 months). One patient (5.3%) developed meta-
stasis to the right iliac bone 5 months after radiotherapy.
The mean preradiation parotid SR was 0.21 ± 0.18 (range,
0.0–0.49), and the mean postradiation parotid SR at 6 months
was 0.12 ±  0.10 (range, 0.0–0.32). A significant difference
(p = 0.002) was found between pre- and postradiation
parotid gland SRs (Figure).
DISCUSSION
Radiotherapy is the main treatment modality for NPC.
Long-term locoregional control rates of more than 70% to
80% have been reported when the disease is treated in the
early stages [2,10]. With the addition of chemotherapy, the
outcome for advanced disease can be improved compared
with radiotherapy alone [13,14]. With this established
efficacy of radiotherapy with or without chemotherapy,
Table 2. Dose (Gy) prescribed and delivered to the targets and critical organs
GTV CTV Parotid Chiasm Spinal cord Brain stem
Right Left
Prescribed* 70.8 ±  1.2 56.1 ±  1.1 34.6 ±  0.8 34.5 ±  0.9 45.2 ±  0.7 40.8 ±  1.4 45.8 ±  1.8
Minimum* 63.9 ±  10 42.0 ±  20 15.6 30.9 16.6 19.5 27.1
Maximum* 74.0 ±  1.8 72.5 ±  10.6 43.6 43.2 59.3 46.6 47.0
Mean* 70.9 ±  1.9 63.2 ±  13.2 37.5 ±  6.6 38.1 ±  3.2 39.9 ±  10.2 36.4 ±  7.2 34.9 ±  4.7
Median* 71.1 ±  1.8 63.8 ±  13.2 36.7 ±  9.5 33.8 ±  3.0 41.7 ±  8.5 39.6 ±  3.6 34.9 ±  4.5
95% volume* 70.0 ±  2.1 55.0 ±  19.7   – – – – –
50% volume* – – 34.9 ±  3.3 34.1 ±  2.9 40.1 ±  9.8 39.4 ±  3.7 34.6 ±  4.6
*Mean ±  standard deviation. GTV = gross tumor volume; CTV = clinical tumor volume.
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prevention of treatment-related sequelae is an important
issue because the number of long-term survivors is
increasing.
Xerostomia, the most frequent late complication, impairs
the quality of life of NPC patients [3,4,15]. It affects speech,
swallowing and chewing, and may increase susceptibility
to dental caries and frequent oral infections [4]. In NPC, the
CTV and PTV volume are adjacent to or even overlap
portions of the bilateral parotid glands. Without IMRT or
3D-CRT, it is difficult to reduce the dose to the parotid
glands. The goal of this study was to test the feasibility of
concurrent chemotherapy with semi-accelerated radio-
therapy using IMRT techniques. We also attempted to pre-
serve parotid function by reducing the dose to the parotid
glands. Mean doses to bilateral parotid glands were slightly
higher than we expected. We also used intracavitary
brachytherapy to boost doses at the primary site of the
nasopharyngeal tumor because the dose contribution to
bilateral parotid glands would be less than 0.5 Gy (5–7% of
prescription dose). The doses to the parotid glands were
much lower than if CRT or IMRT with the same doses had
been used to boost the dose in the nasopharyngeal cavity.
We found that at 6 months after radiotherapy, the mean
postradiation parotid SR (0.12 ± 0.10) was significantly less
than the preradiation SR (0.21 ± 0.18) (p = 0.002).
Several treatment plan comparison studies have concluded
that IMRT plans achieve better parotid gland sparing than
bilateral opposed or 3D-CRT plans [5–7]. Butler et al [8] and
Sultanem et al [10] reported original data for IMRT treatment
of head and neck tumors. In these studies, no patients developed
clinical grade 3 xerostomia. Sultanem et al reported that grade
0 xerostomia developed in 50% of patients and grade 1
xerostomia in 50% [10]. In our series, nine patients (47.4%)
developed grade 1 xerostomia, nine (47.4%) developed grade
2 xerostomia, and one patient (5.3%), who received 3D-CRT
treatment (18 Gy) before IMRT, developed grade 3 xerostomia.
These results are similar to those of Sultanem et al’s [10]. The
mean dose (34.5 Gy) to the left parotid gland was also similar
to the 34 Gy used by Sultanem et al [10]. With a longer follow-
up period, it might be expected that parotid function would be
further improved. The results of objective and subjective
salivary function tests demonstrated that, in a more aggressive
attempt to preserve parotid gland function, lower dose
constraints should be set. In our study, it was below 35 Gy to
the parotid glands.
It is important to appreciate the acute toxic effects of
IMRT and concurrent chemotherapy. In our study, all 12
chemoradiotherapy patients and three radiotherapy alone
patients developed grade III mucositis (79%). Sultanem et al
used a similar fraction size but had a lower percentage of
grade III mucositis (51%) [10]. We offer two reasonable
explanations for this difference. First, the regimens of
concurrent chemotherapy were different: Sultanem et al
used cisplatin alone while we used cisplatin with 5-FU.
Second, the inclusion criteria for chemotherapy were
different: Sultanem et al included 75% of stage III–IV cases
while we included all stage II–IV cases. Although the
incidence of grade III mucositis was 79%, 17 patients
(89.5%) completed the whole course of radiotherapy within
54 days without grade IV mucositis or life-threatening
complications. With careful, supportive management, this
semi-accelerated fractionation plus concurrent chemo-
therapy with cisplatin and 5-FU is safe and practical.
In this study, 36.8% of patients had stage III–IV disease.
The locoregional complete remission rate of 100% was
achieved during a mean follow-up of 13 months. Our finding
is compatible with the results of Sultanem et al [10], who
reported 100% locoregional progression-free survival over
48 months. Although additional investigation with more
patients and a longer follow-up is necessary, IMRT with or
without chemotherapy demonstrated marked improvement
in the preservation of parotid gland function while
maintaining or even improving the locoregional control
rate when compared with conventional treatment.
Figure. Parotid gland saliva secretion ratios for all patients preradiation
(pre-XRT) and postradiation (post-XRT). The bars represent the 95%
confidence intervals for the means, and the central markers (     ) represent
the means. p = 0.002.
Pa
ro
tid
 g
la
nd
 s
ec
re
tio
n 
ra
tio
0.3
0.2
0.1
0.0
Pre-XRT Post-XRT
Kaohsiung J Med Sci February 2004 • Vol 20 • No 2
W.S.Liu, M.C. Su, M.F. Wu, et al
54
CONCLUSIONS
The excellent initial tumor response and decreased damage
to the parotid glands with the combination of IMRT and
chemotherapy suggest that this technique is efficacious as
well as safe for the treatment of NPC. Although IMRT
treatment spares parotid gland function, its efficacy may be
significantly influenced by the disease stage and location of
neck lymph nodes. Future research should incorporate a
larger series of patients and a longer period of follow-up to
better assess these initial promising results.
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